Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-HIV drugs save vision, improve outlook for AIDS patients

14.05.2003


A new study from Johns Hopkins researchers shows the multiple anti-HIV drug regimen called highly active antiretroviral therapy (HAART) saves eyesight as well as lives. A second study led by Johns Hopkins researchers finds that among AIDS patients with longstanding vision problems, those who took HAART reported higher overall quality of life.



The Johns Hopkins team reported in the April issue of Archives of Ophthalmology that AIDS patients who received HAART had a 75 percent lower risk of visual impairment than those who did not. In the second, multicenter study, published in the May issue of the journal Ophthalmology, AIDS patients with vision loss reported a lower vision-related quality of life, although those who took HAART reported higher overall quality of life than those who did not.

AIDS patients are at high risk of vision loss from cytomegalovirus (CMV) retinitis, an infectious disease of the retina. Symptoms include "floaters" and permanent loss of central vision. With HAART, which became available in 1995, many patients’ immune systems seem to recover enough to control CMV retinitis. The condition at one time affected 30 percent of patients at some point during their lives, but has probably decreased to 7.5 percent with the advent of HAART, says John H. Kempen, M.D., Ph.D., lead author of both studies and assistant professor of ophthalmology and epidemiology. By the time CMV is diagnosed, Kempen says, many AIDS patients are already legally blind or have significant vision loss.


"AIDS patients should take HAART as soon as and as much as they can," he says. "HAART often can save both their life and their vision."

In the Archives study, Kempen and his team evaluated 648 AIDS patients seen at the Wilmer Eye Institute at Johns Hopkins between August 1983 and March 2000. Seventeen percent had 20/200 vision (the definition of legal blindness) at the time of diagnosis, while 33 percent had 20/50 vision -- poor enough to restrict their ability to drive. Whites were less likely to have visual impairment, while injection drug users had a higher prevalence of visual impairment. Patients were followed monthly for disease progression.

One year later, 42 percent of 426 patients lost visual acuity equivalent to three lines on the vision chart, 30 percent lost the equivalent of six lines on the chart and 23 percent lost the equivalent of 10 lines on the chart. By one year after CMV retinitis diagnosis, the incidence of vision loss to the level of 20/50 vision was 34 percent and the incidence of vision loss to the level of 20/200 vision was 24 percent. Thus, within the first year after being diagnosed with CMV retinitis, over half (56 percent) had vision loss to the level of 20/50, and about a third (37 percent) were legally blind.

Ninety-three patients (126 eyes) received HAART during the study’s follow-up. Of these, 46 patients (64 eyes) had substantial improvement in their immunity, while 47 (62 eyes) did not. Those who received HAART had a much lower incidence of visual acuity loss compared with patients who did not receive the therapy, especially those who had improvement of their immunity.

In the second study, a report from the Longitudinal Study of Ocular Complications of AIDS, researchers at Johns Hopkins and 18 other centers across the country questioned 971 AIDS patients ages 13 and up about their quality of life related to vision and overall health. Patients were enrolled between September 1998 and March 2001. Fifty patients had newly diagnosed CMV retinitis, 212 patients had longstanding CMV retinitis of an average three years’ duration, and 709 patients had no CMV retinitis. Newly diagnosed patients tended to be female, younger and African-American. They were more likely to have detectable CMV DNA in their blood and had been diagnosed with AIDS more recently, so were less likely to be taking HAART.

The longstanding and newly diagnosed CMV retinitis groups scored substantially worse in vision-related quality of life than the group without CMV retinitis. However, general health-related quality of life scores for the longstanding CMV retinitis group tended to be similar to, or better than, those for patients without CMV retinitis, mostly due to the effects of HAART. Patients with newly diagnosed CMV retinitis tended to score worse on the general health-related quality of life scale.



The risk of vision loss study was supported by the National Eye Institute. Co-authors were Douglas A. Jabs, M.D., M.B.A.; Laura A. Wilson, M.Sc.; James P. Dunn, M.D.; Sheila K. West, Ph.D.; and James A. Tonascia, Ph.D.

The quality of life study also was supported by the National Eye Institute, as well as the National Center for Research Resources. Co-authors were Barbara K. Martin, Ph.D.; Albert W. Wu, M.D., M.P.H.; Bruce Barron, M.D.; Jennifer E. Thorne, M.D.; and Douglas A. Jabs, M.D., M.B.A.

Kempen, J.H. et al, "Risk of Vision Loss in Patients with Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome," Archives of Ophthalmology, April 2003; Vol. 121: pages 466-476.

Kempen, J.H. et al, "The Effect of Cytomegalovirus Retinitis on the Quality of Life of Patients with the Acquired Immune Deficiency Syndrome in the Era of Highly Active Anti-retroviral Therapy," Ophthalmology, May 2003.

Karen Blum | EurekAlert!
Further information:
http://www.wilmer.jhu.edu
http://archopht.ama-assn.org/
http://www.nei.nih.gov

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>